FDA Letter API

Choice Detox Center, Inc. dba Nofeel

Letter data

Company
Choice Detox Center, Inc. dba Nofeel
Recipient
Mr. Kenneth Nersten | Choice Detox Center, Inc. dba Nofeel | Choice Detox Center, Inc. dba Nofeel | 552 Hamilton Street | Suite E-1 | Costa Mesa | , | CA | 92627 | United States
Issue date
2018-09-11
Posted date
Not available
FDA office
Center for Food Safety and Applied Nutrition
Subject
Not available
Product
Drugs
CMS ID
543456
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Choice Detox Center, Inc. dba Nofeel MARCS-CMS 543456 — September 11, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Drugs Recipient: Recipient Name Mr. Kenneth Nersten Choice Detox Center, Inc. dba Nofeel Choice Detox Center, Inc. dba Nofeel 552 Hamilton Street Suite E-1 Costa Mesa , CA 92627 United States Issuing Office: Center for Food Safety and Applied Nutrition 5001 Campus Drive College Park , MD 20740 United States September 11, 2018 Dear Mr. Nersten: The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 543456, issued January 11, 2018. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Carrie Lawlor Branch Chief Dietary Supplement and Labeling Assessment Branch Division of Enforcement Office of Compliance Center for Food Safety and Applied Nutrition Content current as of: 10/15/2018 Regulated Product(s) Drugs